Notably, agonistic antibodies to CD40 have shown efficacy in early-stage trials of pancreatic cancer, in part via their ability to mobilize dendritic cells to present tumour antigens and prime naive T cells [29–32]. The gene discussed is CD40; the disease is familial pancreatic carcinoma.